The multiple faces of NANOG in cancer: a therapeutic target to chemosensitize therapy-resistant cancers.
Homa FatmaHifzur R SiddiqueSantosh K MauryaPublished in: Epigenomics (2021)
The transcription factor NANOG regulates self-renewal and pluripotency in embryonic cells, and its downregulation leads to cell differentiation. Recent studies have linked upregulation of NANOG in various cancers and the regulation of expression of different molecules, and vice versa, to induce proliferation, metastasis, invasion and chemoresistance. Thus NANOG is an oncogene that functions by inducing stem cells' circuitries and heterogeneity in cancers. Understanding NANOG's role in various cancers may lead to it becoming a therapeutic target to halt cancer progression. The NANOG network can also be targeted to resensitize resistant cancer cells to conventional therapies. The current review focuses on NANOG regulation in the various signaling networks leading to cancer progression and chemoresistance, and highlights the therapeutic aspect of targeting NANOG in various cancers.
Keyphrases
- cancer stem cells
- papillary thyroid
- stem cells
- embryonic stem cells
- childhood cancer
- transcription factor
- squamous cell
- signaling pathway
- poor prognosis
- cancer therapy
- induced apoptosis
- squamous cell carcinoma
- lymph node metastasis
- single cell
- drug delivery
- cell therapy
- cell cycle arrest
- binding protein
- cell migration
- cell death
- smoking cessation
- replacement therapy